1: Overall Financial Performance Unit: mb Q1 18 % Q1 19 % Change % YoY Revenue 131.45 100.0% 132.54 100.0% 1.09 0.8% Cost 75.00 57.1% 73.41 55.4% (1.59) (2.1%) Gross Profit 56.45 42.9% 59.13 44.6
Baht 1.37 million or decrease 62.97%, due to the production cost of new production line still not stable and there are some fluctuation. 3. Selling expenses In Q2/2018, the selling expenses was Baht 2.47
of 2019. A summary of the Company’s operating performance in the first quarter of 2020 and 2019 is shown in the following table: 1Q20 4Q19 % Change 1Q19 % Change [Amount in Baht Million] Q-o-Q Y-o-Y
%, compared with the same period of the last year. As a result of operating profit that significant growth and finance costs are very low level because of the stable financial position. DOD BIOTECH PUBLIC
1.50 percent for almost all of 2018 to accommodate domestic economic activity, which is continuing along a stable recovery path. 1.2 Banking Industry and Competition In the second quarter of 2018
Discussion & Analysis Q3/2021 Operating Highlights in Q3/2021 Q3/20 Q3/21 Change +/(-) 9M/20 9M/21 Change +/(-) (THB million) %YoY %YoY Operating Revenue 198 115 (42%) 561 431 (23%) Gross Profit 124 60 (52
have risen abruptly, especially the rapid evolution of digital technology, intensified effects of climate change, and regulatory changes in the financial business. To cope with these issues, most
been a change in the necessary circumstances as provided in the first paragraph, the Minister upon the recommendation of the SEC may modify or change the conditions already specified.
been a change in the necessary circumstances as provided in the first paragraph, the Minister upon the recommendation of the SEC may modify or change the conditions already specified.
Assistance (Addition) and Change of Company Director 28/10/2021 18:00 Interim omitted Dividend, Notification of Entering into a Connected Transaction Regarding the Receipt of Financial Assistance and Change of